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culate TTR, and TTR 55% was defined as “lower TTR”. CHADS22 was defined as
“higher CHADS2”. Logistic regression analyses were conducted to determine the
association between comorbidities and TTR. RESULTS: We identified 23,425 pa-
tients. The mean (SD) age was 74.89.7 years, with 84.8% 65 years. The most
common comorbidities were hypertension (41.7%), diabetes (24.1%), HF (11.7%),
and stroke (11.1%). The mean (SD) TTR was 67.314.4; 18.7% of patients had
“lower TTR”. In multivariable analyses, using age, gender, hypertension, diabetes,
stroke, and region as covariates, HF was associated with “lower TTR” [adjusted OR
(95%CI)  1.41 (1.28, 1.56); p.001]. Diabetes [1.28 (1.19, 1.38); p.001], and stroke
[1.15 (1.04, 1.27); p.001] were also associated with “lower TTR”. In the second
multivariable analyses, using gender, and region as covariates, “higher CHADS2”
was associated with “lower TTR” [adjusted OR (95%CI)  1.11 (1.04, 1.18); p.001].
CONCLUSIONS:Common comorbidities that accompanyNVAF are associatedwith
“lower TTR”. HF was associated with the greatest likelihood of a “lower TTR”, fol-
lowed by diabetes, then stroke. Anticoagulation control is more challenging for
patients with these conditions. Novel agents offering a predictable dose-response
may benefit these patients.
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OBJECTIVES: Patients with Afib have higher risk of stroke than those without Afib.
Anticoagulant therapy prevents strokes in Afib, however, Afib patients with mod-
erate to severe renal impairment have been excluded from trials. The objective of
this study was to assess the distribution of renal function by estimated glomerular
filtration rate (eGFR) in Afib patients. METHODS: A retrospective, cohort design
study was conducted using an EMR database. The study period was January 1996
thru December 2010 [eligibility period: 1/2006 - 12/2009 for adults diagnosed with
Afib (ICD9 code 427.31)]. IndexDatewas first Afib diagnosis during eligibility period.
The pre-index periodwas Jan 1996 to Index and the post-index period defined as 12
months post Index. Serum creatinine measurement at Index was required. Renal
function categorized by NKF Guidelines for Stage of CKD and eGFR calculated using
Cockcroft-Gault Equation. Demographic and clinical characteristicswere collected,
baseline and follow-up renal function determined and logistic regression con-
ducted to assess predictors of renal function decline. RESULTS: A total of 61,840
Afib patients (mean age 69.8 years; 54.2% male) identified and categorized by CKD
stage (mean age; % male) at Index: Normal – 6,572 (58.5; 73.0%); Stage 1 – 10,901
(62.8; 68.6%); Stage 2 – 20,331 (71.3; 58.6%); Stage 3 – 21,105 (74.9; 39.5%); Stage 4 –
2,579 (75.1; 31.1%); Stage 5 – 352 (71.8; 48.9%). Post-index patients were categorized
by CKD stage: Normal – 11,788; Stage 1 – 2799; Stage 2 – 17,009; Stage 3 – 18,849;
Stage 4 – 2675; Stage 5 – 401 (8,319 patients with no post-index eGFR). Male gender
and increasing age and Charlson Comorbidity Index were predictors of renal func-
tion decline (10%) as well as CHD, CKD, DM, HF, HTN and proteinuria (p0.05).
CONCLUSIONS: Nearly 40% of Afib patients in this study exhibited moderate to
severe renal impairment.
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OBJECTIVES: To assess the impact of real life statin utilization on the risk of first
non-fatal myocardial infarction (MI). METHODS: Design: Case-control methodol-
ogy using the pharmacoepidemiological information system “PGRx”. Data on co-
morbidities, risk factors andmedications were obtained frommedical records and
patient telephone interviews. Setting: General practices (n371) and cardiology
centres (n60) across France. Participants: Cases were patients with the first MI 
1 month before the date of recruitment (n2238). Controls were patients seen by a
general practitioner (GP) with no restriction as to the reasons of consultation
(n2238), matched to MI cases on gender, age, frequency of visits to a doctor, date
of recruitment and personal history of non-cardiovascular chronic disease. Expo-
sure: Statin exposure was defined as any utilisation in the two-year prior to date of
MI in cases or recruitment date in controls.Main outcomemeasures: Adjusted odds
ratios (OR) of the risk of first MI was estimated by multiple conditional logistic
regression models. Comparative effectiveness and propensity to use of individual
statinmolecules were assessed. RESULTS: The use of statins was associatedwith a
lower MI risk, with adjusted OR 0.67 [95% CI 0.56 - 0.79] for current use (within 2
months before the index date) and 0.73 [0.62 –0.86] for any use within 24 months.
Among individual statins, rosuvastatin was associated with the lowest MI risk
(adjusted OR 0.49 [0.35 - 0.68] for any use in 24 months preceding the index date)
followed by simvastatin (0.62 [0.46 - 0.84]) and others. CONCLUSIONS: This is the
first major population-based field study to investigate the effect of statins on the
risk of first non-fatal MI in a real life situation. We observed similar risk reduction
as in recent meta-analyses. While most individual statin molecules displayed pro-
tective effect, their effectiveness varied depending onpatient profile and treatment
patterns.
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OBJECTIVES:Although studies have investigated the epidemiology of patientswith
atrial fibrillation (AF), research in Japan is lacking. The aim of the current studywas
to assess the patient characteristics, medication use, and comorbidities of an AF
sample from a representative data source in Japan to make broad cross-region
comparisons.METHODS:The 2008, 2009, and 2010 JapanNational Health andWell-
ness Survey (NHWS) datasets were used in this study. The NHWS is an Internet-
based survey administered to the adult population in Japan using a random strat-
ified sampling framework to ensure demographic representativeness. Only
patients who reported a diagnosis of AF (N565) in these datasets were included in
the analyses. Demographics, health characteristics, stroke risk (using the
CHA2DS2-VASc score), and comorbidities were all assessed. RESULTS: Most pa-
tients were male (83.5%), 60 years or older (77.0%), weighed 64.50 kilograms
(SD11.04), and had been diagnosed for 10.4 years (standard deviation10.6).
Nearly a fifth (19.1%) continued to smoke. Based on the CHA2DS2-VASc score, 11.5%
patients were of low stroke risk, while 35.4% and 53.1% were of moderate and high
risk, respectively. Despite this risk for stroke, only 64.2% of patients were currently
being treated for AF. Patients with AF also reported a number of comorbidities
including 87.1% with another cardiovascular condition, 67.8% with a urological
condition, 37.3% with dyspepsia, and 32.7% with pain. A total of 8.0% of patients
reported a previous myocardial infarction. CONCLUSIONS: The AF population in
Japan is somewhat unique in its dramatic gender split and lower body weight.
Additionally, most AF patients in Japan, through a combination of their behaviors
(e.g., smoking) and health characteristics, are at moderate-to-high risk for a future
stroke. Despite this risk, not all patients are being treated according to current
guidelines. Further, these patients suffer from a number of comorbidities which
can complicate treatment decisions.
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OBJECTIVES:Heart failure (HF) accounts for an excess hospitalization burden in the
United States, and consumption of health care costs. An aging population, eco-
nomic pressures with loss of regular insurance, and increasing co-morbidity
beckon a contemporary analysis of outcomeswithin a nestedMedicaid population.
METHODS: Medical/prescription/enrollment records from the Maryland State
Medicaid Managed Care Organization/Fee-for-service populations were used to
follow 18-64 year olds with a diagnosis of HF between 7-1-05 and 6-30-10 for  6
months. Cox-proportional hazard models assessed the impact of COPD, CVD,
stroke, and renal dysfunction on hospitalization risk post-HF, adjusting for demo-
graphics, disease modifying therapies for HF (ACE inhibitors, ARB, -Blockers, al-
dosterone antagonists, other CV drugs), andwhether diagnosis coincidedwith first
hospitalization. RESULTS: Of 13,192 HF patients, 71% were 45-64 years old, 44%
men, 60% African-American, 26% with first HF diagnosis at first hospitalization.
Patientswith renal dysfunctionweremore likely (HR1.12, p0.001)while patients
with COPD (HR0.85, p0.001) or stroke (HR0.64, p0.001) less likely to be hospi-
talized for HF. There was a lower hospitalization risk among patients who received
ACE inhibitors (HR0.72, p0.001), ARB (HR0.75, p0.001), -Blockers (HR0.81,
p0.001), or other CVmedications (HR0.75, p0.001). Patients diagnosed with HF
at first hospitalization were 2.33 times more likely to be re-hospitalized (p.001)
and risk also increased with age. African-Americans were more likely, than Cau-
casians (HR1.28, p0.001), other races less likely (HR0.60, p0.004), and men
(HR1.13) more likely to be hospitalized. CONCLUSIONS: Renal dysfunction con-
current with HF increased the likelihood of hospitalization, as did age,male gender
and African-American race. Understandably, HF patients on disease-modifying
therapies, but surprisingly those also diagnosed with COPD or stroke, were less
likely to be hospitalized. These findings deserve consideration as disease manage-
ment systems are developed in an era of health care transformation.
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OBJECTIVES:Volumemeasurements of the left ventricle are essential part of echo-
cardiographic diagnosis of canine heart diseases. Three-dimensional echocardiog-
raphy (3DE) has been rarely used in veterinary medicine mainly due to economic
limitations. A new technique now allows a fast semi-automatic direct measure-
ment with 3DE, additionally to the calculation of volumes according to reported
formulas, as used previously. This new method has proven in human medicine to
reveal comparable results to those obtained from the gold standardMRI. MRI is not
indicated in dogs suffering from heart failure, because of the necessity of general
anesthesia. The aim of this study was to compare results from conventional meth-
ods of echocardiographywith 3DE.METHODS: End-diastolic and end-systolic stan-
dard measurements of the left ventricle were performed in 42 healthy dogs (bea-
gles and dachshunds), including calculation of volume according to Teichholz
measurements using M-Mode, calculations of volume using single plane and bi-
plane method of discs (Simpson’s rule) with two-dimensional echocardiography
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(2DE), and biplanemethod of discs frommultiplane images and the frustumof 3DE,
aswell as direct volumemeasurementwith 3DE. Agreement betweenmethodswas
analyzed using amodified Bland-Altman plot. RESULTS:When comparingwith the
direct 3DE measurement of volume, calculated volumes were slightly underesti-
mated with 3DE, and increasingly underestimated with 2DE. However, the devia-
tions were predictable for the respective dog sizes. Results from M-Mode unpre-
dictably overestimated volume of the left ventricle. CONCLUSIONS: When
considering the direct measurement of volume as being the most reliable method,
other measurements performed with 3DE resulted in highest consistency. Results
obtained with 2DE revealed higher but still predictable deviations, whereas results
from M-Mode were highly and unpredictably deviating. Accordingly, 3DE has the
potential to becomeanewstandard in dogs inwhichMRI is not indicated. However,
further clinical and economic evaluations are needed in veterinary cardiology.
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OBJECTIVES: Despite limited evidence, US and European guidelines recommend
the use of IV vasodilators in addition to diuretics for the treatment of acute heart
failure (AHF) patients who are not hypotensive. We investigated whether patients
hospitalized for AHF and treated with IV loop diuretics in combination with IV
nitrates (NT) or IV nesiritide (NES) achieve better outcomes compared to those
receiving diuretics alone.METHODS:UShospital records (2007-2009) from theMar-
ketscan Hospital Drug Database were analyzed to identify patients first observed
hospitalization with a primary diagnosis of AHF. Patients 18 years old, with hy-
potension, cardiogenic shock, myocardial infarction, and acute coronary syn-
dromes were excluded. Patients receiving diuretics were matched pair-wise with
patients receiving diureticsNT or diureticsNES using the propensity score ap-
proach. Outcomes included in-hospital mortality, hospital length of stay (LoS), and
costs during the first AHF hospitalization. RESULTS:DiureticsNT (N4,401; mean
age 70.1 years, 49.2% male) and diureticsNES (N2,254; mean age 70.4 years,
59.4% male) patients had longer LoS (7.3 and 7.9 days, respectively) vs. diuretic
patients (5.7 and 5.8 days for corresponding pairs; p0.01). LoS in ICUwas about 0.7
days longer (p0.01) in both vasodilator cohorts vs. diuretics alone. Mortality was
similar to diuretics patients among diureticsNT patients (1.9% vs. 2.0%; p0.88)
but higher among diureticsNES patients (2.2% vs. 3.1%; p0.05). Hospitalization
costs were significantly greater in both vasodilator cohorts (diuretics: $8,949 vs.
diureticsNT: $14,016, p0.01; diuretics: $9,057 vs. diureticsNES: $14,210,
p0.01). CONCLUSIONS: This real-world study of patients hospitalized for AHF
indicates that neither NT nor NES in addition to diuretics improve survival com-
pared to diuretics alone, and are associated with both longer LoS (1.5 days) and
higher (57%) hospitalization total costs. These data raise the question as towhether
currently utilized IV vasodilators are of value in the treatment of patient hospital-
ized for AHF.
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OBJECTIVES: Cardiovascular health disparities continue to pose a major public
health problem. We hypothesize that the use of existing social networks in hyper-
tension management can help hypertension control rates. Through the Maryland
Cardiovascular Promotion Program (MVP), we evaluated the effect of education
administered within social clusters on the improvement of blood pressure in Afri-
can Americans in the Baltimoremetropolitan area.METHODS:MVP patients, com-
pared to historical controls, were enrolled in the intervention group and asked to
recruit peers to the program and form small groups to attend monthly hyperten-
sion education sessions. Hypertensionwas identifiedwhen systolic blood pressure
(SBP) 140mmHg or/and diastolic blood pressure (DBP) 90mmHg; and SBP 130
mmHg or/and DBP80 mmHg in those with diabetes. We built binary logit regres-
sion models at follow-up of 6, 12, and 18 months, to assess the likelihood of reach-
ing goal (130/80 mmHg for diabetics and 140/90 mmHg for others), controlling for
group assignment, diabetes, smoking, baseline hypertension, and demographics.
We also built regression models for absolute reduction in BP. RESULTS: Out of 530
patients, most were African American. In the adjusted models, the MVP group had
a larger drop in mean absolute SBP than the control, with the gap growing larger
over time. The MVP group was more likely to ever reach treatment goal at 18
months (OR1.72, P0.06), and more likely to reach goal more than once at 12
months (OR2.61, P0.03) and 18 months (OR19.1, P0.001) of follow-up.
CONCLUSIONS: The clustering of patients in social networks around hypertension
education has a positive impact on the management of hypertension. Such ap-
proaches based on existing social networks in minority populations may help im-
prove cardiovascular outcomes and address health disparities.
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OBJECTIVES: Few studies have estimated the dynamic changes and lifetime scores
of quality of life (QOL) among different types of ischemic stroke. The aim of this
study was to quantify these to assist clinical decision. METHODS: The hospital-
based cohort, which consisted of 10,102 patients with first-ever ischemic stroke
during 1995-2007, was classified into 5 types: large artery atherosclerosis (LAA),
lacune, cardioembolism, other determined, and undetermined etiologies. After
linking with the National Mortality Registry 1995-2008, survival function were de-
termined and extrapolated over a 600-month period based on the survival ratio
between the patient’s and age- and sex- matched reference group’s survival as
estimated by a semi-parametric method and hazard functions taken from the vital
statistics of Taiwan. WHOQOL-BREF questionnaire were administered on a cross-
sectional sample of 748 patients to estimate the dynamic changes along different
duration-to-dates. The survival functionswere thenmultipliedwith different facet
scores of QOL to obtain the lifetime scores for patients with different types of
ischemic stroke. Multiple regression analyses were conducted to explore the ef-
fects of different risk factors for QOL after adjustments for age, sex, and education.
RESULTS: Patients with LAA seemed to be affected the most in both survival and
many facets of QOL, as demonstrated by lifetime scores of 35.6 (2.8), 31.7 (3.2), 32.7
(2.5) and 33.2 (3.2) score-months in mobility, positive feelings, sexual activity and
participation in and opportunities for recreation or leisure, respectively. Compared
with other types, cardio-embolism appeared to be affected the most over mobility,
activities of daily living, work ability, thinking and learning. CONCLUSIONS:
Among different types of ischemic stroke, LAA seemed the worst in both QOL and
survival; cardio-embolism showed the longest survival but poor QOL, indicating a
possible greater demand for long term care.
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OBJECTIVES: To examine the relationship between adherence to colesevelam and
risk of major cardiovascular events among hyperlipidemia and/or type 2 diabetes
mellitus (T2DM) patients newly treated with colesevelam. METHODS: The study
sample consisted of hyperlipidemia and/or T2DM patients inMarketScan database
who newly initiated colesevelam with at least 6 and 12 months continuous enroll-
ment prior- and post- drug initiation date in 2007-2010, respectively. Adherence to
colesevelam was measured as Medication Possession Ratio (MPR), calculated as
total days of supply during a one-year period after drug initiation date (adherence
cohort assignment period [ACAP]) divided by 365. Patients were assigned to one of
three adherence cohorts (High: MPR0.8, medium: 0.5MPR0.8, low:
MPR0.5.). The outcome was the time to the first hospitalization with a primary
diagnosis for AMI or stroke during the follow up period from the end of ACAP to the
end of enrollment period in the database. Association of colesevelam adherence
with the outcome was examined by multivariate Cox regression, adjusting for
patient demographic and clinical characteristics. RESULTS: A total of 31,017 pa-
tients were included in the analysis, of which 5,696 (18.4%), 4,643 (15.0%), 20,678
(66.7%) were high, medium and low adherence, respectively. Compared to patients
with low adherence, high adherence patients were 41% less likely to experience
AMI or stroke hospitalization during the follow up period (Hazard Ratio: 0.59; 95%
CI, 0.41 – 0.84, P0.004). Other factors associatedwith significantly lower risk of AMI
or stroke hospitalization included female gender, younger age, absence of baseline
transient ischemic attack or coronary heart disease, absence of concomitant use of
aliskiren, insulin or metformin, and absence of AMI or stroke during ACAP.
CONCLUSIONS: High adherence to colesevelam was associated with significantly
lower risk of major cardiovascular events (AMI and stroke). This finding suggests
that adhering to colesevelam therapy may provide long-term cardiovascular
benefits.
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OBJECTIVES: To evaluate the response to 600 mg Clopidogrel loading dose versus
300 mg loading dose in patients undergo PCI. METHODS: A total of 51 patients
categorized to two groups: Group I consisted of 11 males (64.7%) and 6 females
(35.3%) received 300 mg loading does, while Group II consisted of 28 males (82.4%)
and 6 females (17.6%) received 600mg Clopidogrel loading does. Detection of Clopi-
dogrel response was assessed bymeasuring of the platelet aggregation percentage
and CYP2C19 *2 assay in both groups. Clopidogrel resistance was defined by an
arbitrary cut off value of 10% with respect definition as compared to control value.
RESULTS: The percentage of Clopidogrel response among the studied patients
was 29.2% for 300mg Clopidogrel and 70.8% for 6oomg Clopidogrel loading dose.
In non or poor response to Clopidogrel group 10 patients (37%), were resistance
to 300mg dose and 17 patients (63%) were resistance to 600mg Clopidogrel dose.
Clopidogrel resistance groups were more likely have CYP2C19 genotype
(CYP2C19*1.CYP2C19*2) (GA). There were highly significant association between
good response group, non and poor response groups as regarding to genotype
CYP2C19*1,CYP2C19*1 (GG) carriers and CYP2C19*1,CYP2C19*2 (GA) carriers. Plate-
let aggregation after 600mg Clopidogrel in both CYP2C19*1, CYP2C19*1 (GG) carriers
and CYP2C19*1, CYP2C19*2(GA) carriers is statistically non significant with basal
aggregation, before PCI and after PCI, while significantwith day after PCI andhighly
significant with inhibition percentage before PCI. Platelet aggregation after 300mg
Clopidogrel in both CYP2C19*1, CYP2C19*1 (GG) carriers and CYP2C19*1,
A114 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
